The American Hospital Association, the Association of American Medical Colleges and America's Essential Hospitals today formally notified the court of their intent to appeal the district court’s Dec. 29 decision dismissing the groups’ lawsuit that sought to prevent Medicare payment cuts for many hospitals in the 340B Drug Pricing Program. The associations are joined in the lawsuit by Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. The lawsuit argues that the 340B provisions of the Centers for Medicare & Medicaid Services’ outpatient prospective payment system final rule violate the law and, therefore, should be set aside under the Administrative Procedure Act as unlawful and in excess of the Health and Human Services Secretary’s statutory authority. In that final rule, CMS reduces by nearly 30 percent, or $1.6 billion, Medicare payments to certain hospitals for outpatient drugs purchased under the 340B program. The court’s Dec. 29 ruling was that the lawsuit was brought prematurely, but it did not rule on the merits of the groups’ claim.

Headline
The AHA Aug. 5 provided comments to the Centers for Medicare & Medicaid Services on the distribution of funding for the Rural Health Transformation…
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
A blog by Shannon Wu, AHA director of payment policy, explains why having access to care close to home and the existence of rural hospitals are fundamental…
Blog
Public
Healthcare affordability discussions often focus on premiums, deductibles and drug prices. Those costs matter. But for the more than 46 million Americans who…
Headline
The Senate is expected to vote this week on its own continuing resolution to fund the federal government through Dec. 11. The chamber, scheduled to leave for…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…